GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ASEP Medical Holdings Inc (OTCPK:SEPSF) » Definitions » ROCE %

ASEP Medical Holdings (ASEP Medical Holdings) ROCE % : -38.70% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is ASEP Medical Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ASEP Medical Holdings's annualized ROCE % for the quarter that ended in Dec. 2023 was -38.70%.


ASEP Medical Holdings ROCE % Historical Data

The historical data trend for ASEP Medical Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ASEP Medical Holdings ROCE % Chart

ASEP Medical Holdings Annual Data
Trend Dec21 Dec22 Dec23
ROCE %
-7.34 -19.82 -37.10

ASEP Medical Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.01 -25.51 -46.52 -27.61 -38.70

ASEP Medical Holdings ROCE % Calculation

ASEP Medical Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-7.029/( ( (19.933 - 0.389) + (19.091 - 0.742) )/ 2 )
=-7.029/( (19.544+18.349)/ 2 )
=-7.029/18.9465
=-37.10 %

ASEP Medical Holdings's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-6.864/( ( (17.606 - 0.48) + (19.091 - 0.742) )/ 2 )
=-6.864/( ( 17.126 + 18.349 )/ 2 )
=-6.864/17.7375
=-38.70 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ASEP Medical Holdings  (OTCPK:SEPSF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


ASEP Medical Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of ASEP Medical Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


ASEP Medical Holdings (ASEP Medical Holdings) Business Description

Traded in Other Exchanges
Address
730 View Street, Suite 420, Victoria, BC, CAN, V8W 3Y7
ASEP Medical Holdings Inc is a biotechnology firm pursuing the commercialization of broad-spectrum peptide technology. The Company is dedicated to addressing the global issue of antibiotic failure by developing novel solutions for significant unmet medical needs in human medicine and is engaged in the business of acquiring research and development assets, technology, or businesses in life sciences and medical diagnostics.